Growth Hormone peptide fragment 176-191, also known as HGH Frag
176-191, is a modified form of amino acids 176-191 of the GH
polypeptide. Investigators at Monash University discovered that the
fat-reducing effects of GH appear to be controlled by a small
region near one end of the Growth Hormone molecule. This region,
which consists of amino acids 176-191, is less than 10% of the
total size of the GH molecule and appears to have no effect on
growth or insulin resistance. It works by mimicking the way natural
Growth Hormone regulates fat metabolism but without the adverse
effects on blood sugar or growth that is seen with unmodified
Growth Hormone. Like Growth Hormone, the hgH fragment 176-191
stimulates lipolysis (the breakdown or destruction of fat) and
inhibits lipogenesis (the transformation of nonfat food materials
into body fat) both in laboratory testing and in animals and
humans.

Laboratory Tests and Fat Loss

In laboratory tests on fat cells from rodents, pigs, dogs, and
humans, the hgH fragment released fat specifically from obese fat
cells but not from lean ones, reduced new fat accumulation in all
fat cells, enhanced the burning of fat. In rodents (rats and mice),
hgH fragment reduced body fat in obese animals but, enhanced fat
burning without changing food consumption or inducing growth (as it
does not increase IGF levels) or any other unwanted Growth Hormone
effect. Research dosages of 500mcg of the hgH fragment 176-191
daily for 30 days did show a reduction of body fat in the mid
abdominal area in both obese, over-weight, and average built
people.

Fragment 176-191 as an Active HGH Truncated Peptide

hgH fragment 176-191 is an analog of the growth hormone-releasing
factor (GRF) which signals the effects of growth hormone. It is a
15-mer peptide residue of the C-terminus of HGH to which tyrosine
is added at the N-terminal end. This synthetically produced hormone
is very common to weightlifters and bodybuilders because of a
number of physical benefits. Studies claimed that it actually acts
on the reduction of excessive adipose tissues such as those in the
abdominal area, increase in muscle mass, and enhances the lipid
content of the body.

These segments of the synthetic peptide hgH 176-191 have been
investigated for their in vivo effects in laboratory mice musculus.
Research results have shown that hgH 176-191 have resulted to a
short-period increase in blood glucose and a more sustained
increase in plasma insulin, together with other fragments such as
172-191, 177-191 and 178-191. In addition, the researchers have
suggested that functionality of the peptide depends not only in the
informational sequence but should also have the correct physical
configuration (Ng and Borstein 1978). Also, this fragment, being a
region of high accessibility to proteases and also rich in proline,
have been demonstrated to affect the conformational change in the
cytoplasmic domain of the band 3 of erythrocyte membrane protein by
serving as the hinge for the pivoting of the two subdomains. This
then suggest that such residue is significant in conformational
changes be serving as sites for peripheral protein binding in some
body cells

In another study of Ng et al. (2000) on animal subjects, they found
out that a 500mcg dosage of the said hormone increased the
lipolytic activity in adipose tissues without having negative
influence in the blood glucose level. Furthermore, though it
behaves like a human growth hormone (hgH), it does not causes
hyperglycemia because it does not compete with hgH receptors.
Because of such effects, researchers have suggested that it might
be used for the elimination of excess abdominal fat which is a
significant aspect of HIV-associated lipodystrophy.

The (hgH fragment 176-191) exhibits the ability to burn through
stubborn adipose tissue, while increasing energy expenditure,
muscle mass, and fat oxidation. All studies have pointed to the
fact that the fragment is an effective treatment for obesity and
fat loss, and much safer than its Human Growth Hormone counterpart.